These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 13756725)

  • 21. Isoniazid-associated hepatitis and antiretroviral drugs during tuberculosis prophylaxis in hiv-infected adults in Botswana.
    Tedla Z; Nyirenda S; Peeler C; Agizew T; Sibanda T; Motsamai O; Vernon A; Wells CD; Samandari T
    Am J Respir Crit Care Med; 2010 Jul; 182(2):278-85. PubMed ID: 20378730
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Feasibility and efficacy of isoniazid prophylaxis for latent tuberculosis in HIV-infected clients patients in Thailand.
    Khongphatthanayothin M; Avihingsanon A; Teeratakulpisarn N; Phanuphak N; Buajoom R; Suwanmala P; Phanuphak P
    AIDS Res Hum Retroviruses; 2012 Mar; 28(3):270-5. PubMed ID: 21899431
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Isoniazid hepatotoxicity in renal transplant recipients.
    Antony SJ; Ynares C; Dummer JS
    Clin Transplant; 1997 Feb; 11(1):34-7. PubMed ID: 9067692
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospective randomized control trial of isoniazid chemoprophylaxis during renal replacement therapy.
    Vikrant S; Agarwal SK; Gupta S; Bhowmik D; Tiwari SC; Dash SC; Guleria S; Mehta SN
    Transpl Infect Dis; 2005; 7(3-4):99-108. PubMed ID: 16390397
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Infection prophylaxis in patients with hematological malignancies (II)--Successful prophylaxis of tuberculosis with isoniazid].
    Moriuchi Y; Kamihira S; Satoh T; Yanagisako T; Miyazaki Y; Murata K; Nagai K; Tokunaga S; Maeda T; Atogami S
    Rinsho Ketsueki; 1991 Mar; 32(3):199-204. PubMed ID: 2041164
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circadian-time dependent tolerance and haematological toxicity to isoniazid in murine.
    Souayed N; Chennoufi M; Boughattas F; Hassine M; Ben Attia M; Aouam K; Reinberg A; Boughattas NA
    Biomed Pharmacother; 2015 Apr; 71():233-9. PubMed ID: 25960242
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of isoniazid prophylaxis in renal allograft recipients.
    Naqvi R; Akhtar S; Noor H; Saeed T; Bhatti S; Sheikh R; Ahmed E; Akhtar F; Naqvi A; Rizvi A
    Transplant Proc; 2006 Sep; 38(7):2057-8. PubMed ID: 16979998
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Isoniazid Resistance and Dosage as Treatment for Patients with Tuberculosis.
    Nagel S; Streicher EM; Klopper M; Warren RM; Van Helden PD
    Curr Drug Metab; 2017; 18(11):1030-1039. PubMed ID: 29086682
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Advance in chemoprophylaxis of tuberculoio with isoniazid].
    ZORINI AO; SPINA G; LUCCHESI M
    Cas Lek Cesk; 1961 Aug; 100():1010-4. PubMed ID: 13831390
    [No Abstract]   [Full Text] [Related]  

  • 30. ONLY isoniazid.
    Lancet; 1960 May; 1(7132):1013-5. PubMed ID: 13857536
    [No Abstract]   [Full Text] [Related]  

  • 31. Characteristics of mycobacterial populations found in the sputum of tuberculous patients after prolonged isoniazid therapy.
    PEIZER LR; CHAVES AD; WIDELOCK D
    Am Rev Respir Dis; 1960 Oct; 82():568-73. PubMed ID: 13733935
    [No Abstract]   [Full Text] [Related]  

  • 32. Retreatment of tuberculous patients: an experience with the combined use of high doses of isoniazid, pyrazinamide and cycloserine.
    SALIBA A; BEATTY OA
    South Med J; 1961 Jan; 54():10-6. PubMed ID: 13745634
    [No Abstract]   [Full Text] [Related]  

  • 33. Twelve-Week Rifapentine Plus Isoniazid Versus 9-Month Isoniazid for the Treatment of Latent Tuberculosis in Renal Transplant Candidates.
    Simkins J; Abbo LM; Camargo JF; Rosa R; Morris MI
    Transplantation; 2017 Jun; 101(6):1468-1472. PubMed ID: 27548035
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is isoniazid safe for liver transplant candidates with latent tuberculosis?
    Stucchi RS; Boin IF; Angerami RN; Zanaga L; Ataide EC; Udo EY
    Transplant Proc; 2012 Oct; 44(8):2406-10. PubMed ID: 23026607
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ameliorating role of caffeic acid phenethyl ester (CAPE) against isoniazid-induced oxidative damage in red blood cells.
    Gokalp O; Uz E; Cicek E; Yilmaz HR; Ozer MK; Altunbas A; Ozcelik N
    Mol Cell Biochem; 2006 Oct; 290(1-2):55-9. PubMed ID: 16964438
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A simple spot test to determine whether a patient is taking isoniazid.
    KASIK JE; HELLER A; LESTER W; BARCLAY WR
    Am Rev Respir Dis; 1962 Feb; 85():282-4. PubMed ID: 14454151
    [No Abstract]   [Full Text] [Related]  

  • 37. [Isoniazid (INH) prophylaxis].
    KLEINSCHMIDT H
    Med Welt; 1960 Sep; 36():1809-12. PubMed ID: 13756725
    [No Abstract]   [Full Text] [Related]  

  • 38. INH prophylaxis and treatment in bovines.
    DORMER BA; MARTINAGLIA G; HOBBS WB
    S Afr Med J; 1961 May; 35():429-31. PubMed ID: 13723919
    [No Abstract]   [Full Text] [Related]  

  • 39. [Clinical studies of INH-on the role of INH in combination with SM, PAS, and INH with special reference to the role of INH].
    OKA S
    Kekkaku; 1961 Aug; 36():512-20. PubMed ID: 13730558
    [No Abstract]   [Full Text] [Related]  

  • 40. [Clinical study of INH].
    KAWAMORI Y
    Kekkaku; 1961 Aug; 36():503-7. PubMed ID: 13751976
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.